INTRODUCTION
Spinal muscular atrophy (SMA) is a devastating childhood neuromuscular disease that leads to early death in the most severe cases 1, 2 . As an autosomal recessive disease, SMA is caused by loss of the survival motor neuron 1 (SMN1) gene due to either mutations or deletions 3 . While a total deficiency in the SMN protein is embryonic lethal 4 , humans have a duplicated copy of SMN1, termed SMN2 3 , which allows for survival in the absence of the former. However, SMN2 contains a key C to T transition in exon 7 that leads to its excision in approximately 90% of the transcripts produced, generating a non-functional SMNΔ7 protein that is rapidly degraded 5, 6 . Importantly, the 10% of fully functional full length SMN protein produced from SMN2 is sufficient to allow survival, albeit not sufficient to prevent neuromuscular degeneration 7 .
The first genetic therapy for SMA, nusinersen/Spinraza™, was approved in December 2016 by the Food and Drug Administration (FDA) and in June 2017 by the European Medicines Agency 8 . This antisense oligonucleotide is delivered directly to the central nervous system (CNS) via a lumbar puncture and is aimed at promoting SMN2 exon 7 inclusion 9 .
Zolgensma® is a single, systemic of delivery of SMN1 via an adeno-associated virus serotype 9 (AAV9) gene therapy that received FDA approval in May 2019 10 . Additional SMN-enhancing pharmacological compounds are also in the pipeline and anticipated to be approved for patient use in the near future 11 . While the benefits of these SMN-dependent drugs are undeniably remarkable, it is appreciated that they unfortunately do not represent a cure and will have to be supported by additional non-CNS and -SMN therapeutic interventions to provide optimal care to all SMA patients [12] [13] [14] [15] .
SMN-depleted skeletal muscle displays both cell-autonomous and non-autonomous defects 16, 17 and is therefore an important therapeutic target for SMA. We have recently demonstrated the dysregulated expression of the transcription factor Krüppel-like factor 15 (Klf15) in skeletal muscle of SMA mice during disease progression 18 . KLF15 is crucial in the regulation of skeletal muscle metabolism and ergogenic properties [19] [20] [21] [22] . Specifically, we observed a significant downregulation of Klf15 expression in pre-symptomatic SMA mice and found that its neonatal upregulation via pharmacological (prednisolone) or transgenic (muscle-specific Klf15-overexpression) interventions significantly improved several disease phenotypes in SMA mice 18 . However, prednisolone has pleiotropic activities and constitutive embryonic overexpression of Klf15 in skeletal muscle of SMA may have resulted in compensatory mechanisms 23 . In this study, we thus set out to overexpress Klf15 in skeletal muscle of neonatal SMA mice via a self-complementary adeno-associated virus serotype 2/8 and the Spc5-12 promoter. While this strategy led to substantial Klf15 expression in skeletal muscle of SMA mice and control littermates, there were no associated significant improvements in disease phenotypes. Nevertheless, AAV8-Klf15 injections resulted in pronounced expression as early as post-natal day 2 in several tissues including muscle, liver and heart, highlighting the potential of this specific viral construct for efficient perinatal delivery.
MATERIALS AND METHODS

Animals
Wild-type (WT) FVB/N mice were used for initial expression screening. 
Sc-AAV2/8-Spc5-12 constructs
The generation of the self-complementary adeno-associated virus serotype 2/8 (scAAV2/8) vectors and quality control were performed by Atlantic Gene Therapies (Nantes, France).
The synthetic Spc5-12 promoter 27 was used to drive the expression of eGFP or a codon- 
C2C12 cell line
C2C12 myoblast cells 28 
Immunocytochemistry and immunohistochemistry
C2C12 cells transduced with the eGFP-expressing AAV vector were imaged live with a DM IRB microscope (Leica).
Quadriceps muscles were harvested at the indicated time points during disease progression, fixed in 4% paraformaldehyde, cryopreserved in 30% sucrose, and cryosectioned at a thickness of 12 μM. The sections were immunostained with chicken anti-GFP antibody (1:3000, Abcam) and detected with Alexa-488-conjugated anti-chicken secondary antibody
(1:5000, Life technologies). Images were taken with an Olympus Fluoview FV1000 confocal microscope and processed with Fiji 30 .
Statistics
All statistical analyses were performed using GraphPad Prism version 8. 
RESULTS
Muscle-specific Klf15 expression with a scAAV2/8-Spc5-12 viral vector
To specifically induce Klf15 expression in skeletal muscle, we utilized a self-complementary adeno associated virus serotype 2/8 driven by the synthetic muscle-specific promoter Spc5-12 27 (scAAV2/8-Spc5-12-Klf15, henceforth termed AAV8-Klf15). This combination of AAV and promoter has previously successfully been used for gene delivery to muscles for treatment of the muscle disorder Duchenne muscular dystrophy (DMD) 31 . A control scAAV2/8-Spc5-12-GFP construct was also generated (henceforth termed AAV8-GFP).
We first examined the transduction ability of the AAV8-GFP construct in differentiated C2C12 myoblasts 28 . The cells were transduced with AAV8-GFP (multiplicity of infection (MOI) 1E10 5 ) for 3 days and assessed for GFP expression compared to untreated cells.
Both flow cytometry and live imaging analyses confirm the abundant presence of GFP in AAV8-transduced cells (Fig 1a,b) . Differentiated C2C12s transduced with AAV8-Klf15 (MOI 1E10 5 ) demonstrate a significant increased expression of Klf15 mRNA compared to untreated cells (Fig 1c) . Data are scatter plot and mean ± SEM, n = 4-5 animals per experimental group, unpaired t test, *p = 0.028 (P2), **p = 0.0076 (P7). e. Representative images of cross-sections (P2) and
longitudinal sections (P7) of quadriceps immunostained for GFP from P2 and P7 untreated WT animals and WT mice that received a facial intravenous injection of AAV8-GFP (1E11 vg/pup) at P0.
To determine if our constructs would also be active at early time points in muscle of neonatal mice, we administered AAV8-GFP (1E11 vg/pup) to P0 wild type (WT) pups via a facial vein intravenous injection 26 . Quadriceps muscles were harvested from injected and non-injected WT littermates at P2 and P7. P2 represents the pre-symptomatic age at which we have observed a significant downregulation of Klf15 in the Taiwanese Smn -/-;SMN2 SMA mice 18, 24 while P7 is considered a late symptomatic time point. qPCR analysis shows a significant upregulation of GFP expression at both P2 and P7, albeit variable between animals, with increased levels at the later time point (Fig 1d) . Immunohistochemistry of P2 and P7 quadriceps also reveals a time-dependent increased expression of GFP in AAV8-treated animals compared to untreated littermates (Fig 1e) . Combined, our experiments in C2C12s and WT mice demonstrate the ability of our viral vectors to induce Klf15 and GFP expression in differentiated skeletal muscle.
Neonatal administration of AAV8-Klf15 to severe SMA mice does not improve weight or survival
We next wanted to determine if increasing early postnatal Klf15 expression in the Smn -/-;SMN2 SMA mice would influence disease progression. Administering 1E11 vg/pup of AAV8-Klf15 to P0 Smn -/-;SMN2 mice and Smn +/-;SMN2 control littermates revealed itself to be toxic (spontaneous death without any impact on weight) to both genotypes (data not shown). Seeing as this dose was not harmful with AAV8-GFP, the adverse effects are most likely due to the supraphysiological levels of Klf15. We therefore reduced the AAV8-GFP and AAV8-Klf15 dose to 2E10 vg/pup for subsequent administrations, which still allowed for an age-dependent increased expression of GFP (Fig 2a) and Klf15 (Fig 2b) , albeit with some variability between animals, in quadriceps of P2 and P7 Smn +/-;SMN2 and Smn -/-;SMN2 mice. In terms of effects on disease progression, we found that AAV8-Klf15-treated Smn -/-;SMN2 mice survived longer than untreated Smn -/-;SMN2 (Fig 2c) . However, AAV8-GFP-treated Smn -/-;SMN2 mice also display a moderately improved lifespan (Fig 2c) , suggesting that the AAV construct itself has some beneficial physiological impact. Interestingly, we also observed that Smn -/-;SMN2 mice that received the AAV8-GFP weighed slightly more than AAV8-Klf15-treated and untreated Smn -/-;SMN2 (Fig 2d) .
We found no significant differences between the survival of untreated, AAV8-GFP-treated and AAV8-Klf15-treated Smn +/-;SMN2 mice (Fig 2e) , although a small number of spontaneous deaths occurred in all cohorts. Similar to what we observed in the Smn -/-;SMN2 mice, AAV8-GFP-treated Smn +/-;SMN2 mice weighed slightly more than untreated and AAV8-Klf15-treated Smn +/-;SMN2 mice during the P0-P21 pre-weaning phase (Fig 2f) .
However, this increased weight was not maintained post-weaning (Fig 2g) . We did observe a small but significant increase in weight of AAV8-Klf15-treated Smn +/-;SMN2 mice at 6 months of age. Thus, administering a perinatal injection of AAV8-Klf15 at a dose of 2E10 vg/pup significantly increases Klf15 expression in skeletal muscle without having overt adverse or beneficial effects on survival.
Neonatal administration of AAV8-Klf15 to intermediate SMA mice slightly improves survival
Due to the severe and rapid disease progression in the Smn -/-;SMN2 mice, they respond less favorably to non-SMN treatment strategies compared to the milder intermediate Smn 2B/mouse model 18, 25, 32, 33 . We therefore proceeded to evaluate the effect of AAV8-Klf15 in Smn 2B/mice and Smn 2B/+ control littermates, following the same dosing regimen as in the severe SMA mice. Similar to what was observed in the Smn -/-;SMN2 mice, AAV8-GFPtreated Smn 2B/mice also demonstrated a small but significant increase in survival compared to untreated Smn 2B/mice (Fig 3a) . Interestingly, AAV8-Klf15-treated Smn 2B/mice had a significantly increased lifespan compared to both untreated and AAV8-GFP-treated Smn 2B/mice (Fig 3a) . While AAV8-Klf15 did not influence the weight of Smn 2B/mice during the nursing period (up to P21), an increase in weight could be seen in the post-weaned mice (Fig 3b) . However, that weight gain did not ultimately prevent an early death. Interestingly, AAV8-GFP-treated Smn 2B/mice were significantly heavier than untreated and AAV8-Klf15treated Smn 2B/mice (Fig 3b) between P13-21, again similar to what we found in the Smn -/-;SMN2 mice. We did not observe any effects of AAV8-GFP or AAV8-Klf15 on the weights of pre-weaned Smn 2B/mice compared to untreated animals (Fig 3c) . Thus, the AAV8-Klf15 was slightly more beneficial in the intermediate Smn 2B/-SMA mouse model than the severe Taiwanese Smn -/-;SMN2 mice, overall. Smn 2B/+ mice. Data are mean ± SEM, two-way ANOVA, ns = not significant.
The AAV8-Spc5-12 construct also induces expression in heart and liver
While the synthetic Spc5-12 promoter has been used for its enhanced activity in skeletal muscle 27, 31 , we wanted to determine if our AAV8 delivery system also induced expression in heart and liver, tissues in which Klf15 also plays key roles 34, 35 . We indeed observed significant increased expression of GFP and Klf15 mRNA in the livers of both P2 and P7
AAV8-GFP- (Fig 4a) and AAV8-Klf15-treated (Fig 4b) Smn +/-;SMN2 and Smn -/-;SMN2 mice compared to untreated animals. This increase was approximately 15 times (GFP) and 10 times (Klf15) higher than in skeletal muscle for both time points. Similarly, we find a significant upregulation of GFP and Klf15 mRNA in the hearts of AAV9-GFP- (Fig 4c) and
AAV8-Klf15-treated (Fig 4d) P2 and P7 Smn +/-;SMN2 and Smn -/-;SMN2 mice compared to untreated animals. Surprisingly, the increase in heart was approximately 40 times (GFP) and 50 times (Klf15) higher at P2 while in was approximately 70 times (GFP) and 10 times (Klf15) higher at P7 compared to skeletal muscle at those respective time points. Of note, there was some variability between animals within the same experimental group. Therefore, our results demonstrate that the activity of the AAV8-Spc5-12 vector is not exclusive to skeletal muscle. 
DISCUSSION
We have recently demonstrated that Klf15 expression is significantly downregulated in muscle of pre-symptomatic SMA mice and that upregulating Klf15 expression via genetic (transgenic muscle-specific expression) or pharmacological (prednisolone) approaches results in improved disease phenotypes 18 . Here, we evaluated the impact of specifically Klf15 can display both atrophy-inducing 36 and ergogenic 19 properties in skeletal muscle in a dose-dependent manner 37 , it is quite possible that the supraphysiological levels achieved with AAV8-Klf15 favor muscle wasting over growth. We also note significantly more variability in Klf15 levels in animals injected with the AAV8 construct compared to the transgenic mice ( Fig 2) 18 , which are most likely due to differential injection efficiencies and/or vector spread and could influence physiological outcomes.
We have previously shown that administration of prednisolone to SMA mice also increases Klf15 levels in skeletal muscle of P2 pre-symptomatic animals (~ 6 fold greater than untreated controls) 18 . However, this effect on Klf15 induction ceased at P7, specifically in SMA mice 18 , suggesting that prednisolone-dependent benefits in symptomatic SMA mice may be due to KLF15-independent effects and/or that prednisolone-dependent Klf15 increase in P7 animals may be limited by compensatory inhibitory mechanisms due to already significantly increased Klf15 levels in symptomatic SMA mice compared to controls 18 . It is therefore possible that an optimal strategy would be to conditionally increase Klf15 expression in pre-symptomatic stages only, which is not easily achieved as the kinetics of AAV-mediated overexpression require several days for efficient transgene activity. To achieve optimal expression at early pre-symptomatic post-natal stages may therefore require pre-natal delivery.
While our AAV8 construct was designed to overexpress Klf15 specifically in skeletal muscle, our analysis of heart and liver demonstrate significantly higher activity in these tissues ( Fig   4) . KLF15 has well described roles in heart and liver 34, 35 , suggesting that its increased expression via our AAV8 construct, most likely also impacts the function of these tissues.
SMA mice display several heart and liver pathologies 38, 39 , suggesting that aberrant KLF15 levels may have non-intended organ-specific adverse effects, which most likely explain the spontaneous deaths observed in our mice treated with the high vector dose. Furthermore, we have previously reported increased levels of Klf15 in the liver and heart of symptomatic mice 18 , which most likely reflect a pathological response.
Surprisingly, the AAV8-GFP construct also demonstrated some non-negligible effects on disease phenotypes of SMA mice (Fig 3) . While we cannot be certain as to why that is, we speculate that it may be related to possible effects on the immune system, similarly to previous reports for AAV8 vectors 40, 41 . Seeing as SMA mice have an altered immune response 42, 43 and that inflammation can display both protective and adverse systemic properties 44 , including the CNS 45 and muscle 46 , it is possible that an activated immune response results in acute and/or intermittent benefits in AAV8-treated SMA animals.
In summary, the limited impact of AAV8-Klf15 administration in SMA mice might be explained by several experimental conditions that most likely reduced our ability to increase Klf15 specifically in skeletal muscle at physiological levels and with the optimal timing, without influencing the function of other tissues and systems. In the experimental paradigms tested here, the positive, albeit small, effect on survival and weight was restricted to the milder Smn 2B/-SMA mouse model. 
